Recentl y, leukotrienes have be en imp lica ted in the mediation ofbronchoconstriction and inflanunatory cha nges in asthma . Leukotrien e levels ha ve also been sho wn to be elevated in patients wi th asthma as well as in those with sinonasa l po lyposis and sinus itis. The leukotri ene synthesis inhibito r zileuton and the leu kotri ene recep tor antagonist zafi rlukast have been shown to produce subj ective and objective improvements in patients with m ild to moderate asthma . Given thesefindings, we evaluated the efficacy ofthese two medications in co ntrolling sinonasal polyp osis and their associated sytnptoms.
Introduction
Leuk otr ienes are cytok ines, whi ch belong to a larger group of mol ecul es known as eicosanoids. Th ey are deriv ed from arachado nic acid, a fatty ac id that is attached to cell memb rane phosph olipid s in a variety of mammalian eelis. Leukotrienes have been implica ted in the pathogenesis of asthma in that they ca use bronchocon strict ion , increase mucosal edema and mucus produ ction, and stimulate inflammato ry ee li infiltration. !" Furtherm o re, leukotriene synthesis inhibitors and leukotriene receptor antagonists have pro duce d clin ica lly significant improvements in patien ts with mild to moderate asthma." "
The etio log ic factors that cau se sinonasal polyposis are stiil uncl ear, but there is ev idence that cell-med iated immunity migh t play a role in its pathogenesis.!"!' Leukotr ien es have been shown to be eleva ted in some patie nts with sinonasa l polyposis, es pec ially those in whom polyp osis defi es conventional mod alities of treatment.":" Th ese mod aliti es include ora l and topieal steroids, immune modulators such as antihistamines, and desensiti zation and repeated surgical deb ridemen t. Although these modalities are effec tive in most patient s, undesirab le surg ica l co mplica tions and adve rse side effects from the long-terrn use of medi cation s ca n occ ur.
No studies to date have add ressed the possible role of antileuko trienes in the control of sinonas al polyposis and sinusitis. In this preliminary study, we have begun to address the use of two specific antileukot rienes, zileuton and zafirlukas t, in the manage me nt of sinonasal polyposis and sinusitis.
Materials and methods
We treated 40 patien ts who had sino nas al polypo sis and sinusitis with one of two ant ileukotriene s: zafirlukas t (20 mg po bid) 01' zileuto n (600 mg po qid). Th e cho ice of medication was determin ed by the surgeon's preference. Live r funct ion tests were obtai ned on all patie nts I mon th followi ng the start of medication . Patient s were otherwi se managed in a routine mann er typ ical of the standard treatment for sino nasa l polyp osis and sinusitis , including endoscopic ex aminatio ns. 
Power[P®®O'
Symptom s were assessed by in-person and telephone interviews as well as by questionnaire responses. In the questionnaire, patients were asked to assess the sever ity and duration of 22 different symptoms: sinus headache, facial pain and pressure, ear pain and pressure, toothache, clear rhinorrhea, purul ent rhinorrhea, postnasal drip , nasai congestion and obstruction, olfaction, fever, fatigue, irritability, cough, sore throat, chills, myalgia, epiph ora, itchy eyes, and ophthalmoplegia. Data were analyzed with the Wilco xon matched-pairs test.
Results
Thirt y-six patients were available for evalu ation . They had been followed for at least I month while on the medication. The mean duration of medic ation use was 7.4 months. All patients had been diagno sed with sinonasal polyposis and chronic sinusitis. Fourteen ofthese patients had also been diagnosed with asthma, including two who had Samter' s triad (sinonasal polypo sis, asthma, and aspirin sensitivity). Twenty-six patients were prescribed zafirl ukast, five were given zileuton, and five who started on zafirlukast subsequently were switched to zileuton , because of either a lack of response or adverse effects. Oral steroids had been or were being used by 26 patient s. Thirty patie nts completed a thorough questionn aire regarding the severity and duration of sinonasal symptomatology.
Overall, 26 of the 36 patients (72%) experienced improvem ent in their sy mpto ma to logy after star ting antileukotriene therapy. No patient experienced a worsening of symptoms. The remaining 10 patients (28%) experienced no chan ge. With respeet to the two different medications, 19of the 26 patients who started on zafirlukast experienced overall improv ement (73%), while the remaining seven noticed no change. Ofthe five patients who were switched from zafirluk ast to zileuton , two (40%) experienced impro vement after the switch.
With respeet to specific symptoms among the entire gro up, significant improvement was see n in terms of sinus headache (p <O.OI), facial pain (p<0.05) , facial pressure (p<0 .05), ear pain and pressure (p<0.0 1), dent algia There were significant improvements (p<0.01) in the duration of some symptoms-specifically, sinus headache, purul ent anterior nasal discharge, postnasal drip , nasal congestion, nasal obstruction, and olfaction.
A subjective improvement in the degree of sinon asal polyposis was observed in 18 patients (50%); no chang e was seen in 15 (42%), and a worsening was seen in three (8%). To dat e, 15 of the 26 patients (58%) who had previously required oral steroids for polyp control have 20 not required furthe r steroid therapy. There were no statistically significant differenc es in outcomes between the group of 14 patients who had asthma and the group of 22 who did not.
With respeet to drug-related adverse effects, five patients reported dryness (13.9%), four patient s reported headache (1 1%), three each reported myalgia and gastrointe stinal upset (8.3%), and two each reported dizziness and nausea (5.5%). One patient each experienced Iympho cytosis, increased salivation, cough , fatigue , and palpitations (2.7%) . Finall y, one patient reported a combinat ion of decreased libido, impro ved memory, and insomni a. Four patients were forced to discontinue drug therapy becau se of side effects , including one patient on zafirlukast who experi enced an elevation in liver enzyme levels.
Discussion
The etiology and pathophysiolog y of sinonasal polyposis has yet to be clearl y elucidated. There is evidence that cell-rnediated immunity might play a role in its pathogenesis.!':" There are distinctl y different categories of polyps that occur in the nose and sinuses, the vast majority of which are related to allergies and asthma. A small pereent age of patients has Samter' s triad.
Patients with sinonasa l polyposis and patient s with asthma all have ele vated leukotriene level s. In recent years, the significant role that leukotri enes play in the pathogene sis of asthma has been clarified.!" Leukotriene production has been shown to con strict airway smooth muscle, increase muco sal edem a via vascular leakage , and increa se mucu s production. Leukotrienes also stimulate the infiltration of inflammatory cells, such as eosinophils, mast cells, and basophils, in which leukotrienes are found in great concentrations. Although the role of high leukotriene level s in patients with asthma has been examined," !' its role in sinonasal polyposis has not received as much attention.":"
The purpose of this prelimin ary report is to docum ent the progress of our ongoing investigation into the use of zileuton and zafirlukast as therapeutic options in the management of sinonasal polyposis and sinusitis.
Mechanisms of action. The synthesis of leukot rienes
begins with the clea vage of arachadonic acid from cell membranes via the action of phospholip ase A r Intracellularly, arachadonic acid is converted sequentially to 5hydroperoxyeicos atetraenoic acid (5-HPETE) and then to leuk otriene A 4 (LTA 4 ) by 5-lip oxygenase and 5lipoxygenase-activ ating protein. LTA 4 is converted to leukotriene C4 (LTC4) synthase, and is then transported into the extracellular microen vironm ent, where it is con- 
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PARNES, C HUMA (LTE). LTC~, LTD~, and L TE~all co ntain cysteine and are known as cysteinyl ieukotrienes (C-LTs). (Previously, these three leukotr iene s were known collective ly as the slow-reactive substance of anaphylaxis , whic h was implicated in the pathophysiology of allergy and allergic reactions). Cells known to produce and store large amounts of C-LTs are mast cells, eosinophils, mac rophages, and basophil s. Th e target recepto r for C-LTs, which lead to the cascade of eve nts that result in allergic reaction s as weil as airway hyperresponsiveness in asthmatics, is the cys teinyl leukotriene receptor type I (CysLt). Leukotriene produ ction can be inhibited by targetin g any of the enzymes along the pathway that lead s to it. The only enzy me that has been successfully inhibited thus far is 5-lipoxygenase. Thi s enzyme prevent s the con version of arachad onic acid to 5-HPETE, which is subsequently co nverted to LTA~. Anoth er successful meth od of blocking the action of leukotrienes is to selectively block the receptor CysLt I • In our study , we used two different medic ations: zileuton and zafirlukast. Zileuton, a 5lip oxygen ase inh ibitor, pre vents th e form ation of leuk otrienes. Zafirluk ast, a CysLt I receptor antagoni st, block s leukotriene acti vity by preventing it from bind ing to the recept or. Alth ough these medi cations have different modes of action, both prevent leukotriene activity.
Th erapeutic effieaey. Our study showed that in patient s with sinonasa l polyposis and sinusitis, certain symptoms improved significantly after antileukotriene therapy was initiated. These symptoms were sinus headache, facia l pain and pressure, ear pain and pressure , dent al pain, purul ent anter ior nasal disch arge, postnasal drip , nasal conges tion, nasal obstruc tion, olfacti on, and fever. With respeet to their dur ation, symptoms that showed statistically sign ificant improvement were sinu s headache, purul ent anterior nasal disch arge, postnasal drip, nasal congest ion, nasal obstructi on , and olfaction.
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